Aviva Holdings’s PTC Therapeutics PTCT Stock Holding History

Aviva Holdings’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-87,330	Closed	-$2.36M	–	7
2018 Q1	$2.36M	Buy	+87,330	New	+$2.21M	0.96%	5

Other funds holding PTCT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Aviva Holdings's PTCT Position: Q2 2018 in Review

Aviva Holdings sold out of PTC Therapeutics (PTCT) in Q2 2018, closing a stake of 87,330 shares — an estimated $2.36M sold.

Aviva Holdings first reported a position in PTCT in Q1 2018 and held it in 1 quarter. The position peaked at $2.36M in Q1 2018. 166 funds tracked by Wall St. Rank hold PTCT as of Q2 2018.

Aviva Holdings reported no remaining PTC Therapeutics position as of Q2 2018 after selling out during the quarter.
Aviva Holdings sold 87,330 PTC Therapeutics shares in Q2 2018, an estimated $2.36M.
Aviva Holdings first reported a position in PTC Therapeutics in Q1 2018 and held it in 1 quarter.
Aviva Holdings's PTC Therapeutics position peaked at $2.36M in Q1 2018.
166 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2018.

Based on Aviva Holdings's 13F filing for Q2 2018, filed 14 Aug 2018.